BRCA Gene Changes: Cancer Risk and Genetic Testing
A fact sheet about the BRCA1 and BRCA2 genes, what to do if a person tests positive for alterations in one of these genes, and consequences of genetic testing.
BRCA1 and BRCA2 (PDQ®) - NCI - National Cancer Institute
Evidence-based, expert-reviewed summary about the BRCA1 and BRCA2 genes and hereditary breast and ovarian cancer. This summary also contains information about the cancer risks associated with BRCA1/BRCA2, screening, risk-reduction, treatment, and prognosis.
Mutaciones en el gen BRCA: el riesgo de cáncer y las pruebas …
Hoja informativa sobre los genes BRCA1 y BRCA2, qué hacer si la prueba de una persona indica que tiene cambios en uno de estos genes y las consecuencias de las pruebas genéticas.
Definition of BRCA1 gene - NCI Dictionary of Cancer Terms
A gene that makes a protein that repairs damaged DNA. Mutations (changes) in the BRCA1 gene significantly increase the risk of developing breast and ovarian cancer.
Discovery – BRCA Connection to Breast and Ovarian Cancer
NCI-funded research helped identify inherited BRCA1 and BRCA2 genetic mutations and their connection to breast and ovarian cancer. From this research, a screening test was also developed to help patients make informed decisions about their health.
MRI, Surgery Reduce Cancer Deaths in Women with BRCA Changes
2024年4月15日 · Those with harmful BRCA1 or BRCA2 changes who had the surgery, the study found, had a lower risk of dying from ovarian cancer and breast cancer than those who didn’t. Results from both studies were published February 29 in JAMA Oncology.
PALB2 and Associated Cancer Risks (PDQ®) - NCI
This gene interacts with both BRCA2 and BRCA1 to restore and maintain genomic stability via homologous recombination repair of DNA double-stranded breaks. Several studies have reported a high penetrance of breast cancer in women who carry PALB2 pathogenic variants. PALB2 is now included on all breast cancer multigene panel tests.
Olaparib Approved for Breast Cancers with BRCA Gene Mutations
2018年1月29日 · The Food and Drug Administration has approved olaparib (Lynparza®) to treat metastatic breast cancers that have inherited mutations in the BRCA1 or BRCA2 genes as well as a companion diagnostic test for selecting candidates for the therapy.
Cancer Risk for Women Carrying BRCA Mutations - NCI
2017年7月12日 · Women who know they have inherited a harmful BRCA1 or BRCA2 mutation can take steps to reduce their risk of breast and ovarian cancer. But any preventive measures—including intensive early surveillance , use of chemoprevention , and prophylactic surgery —come with their own risks.
Clinical trial researching BRCA1-Associated Protein-1 mutations
2024年2月13日 · A clinical trial led by David S. Schrump, M.D., M.B.A., FACS, Chief and Senior Investigator in the Thoracic Surgery Branch, is researching a combination drug therapy for BRCA1-Associated Protein-1 mutations.